摘要
目的研究交泰丸中小檗碱联合cinnamtannin D1的降血糖作用。方法 40只db/db小鼠随机分为对照组(0. 5%CMC-Na)、二甲双胍组(150 mg/kg)、小檗碱组(200 mg/kg)、小檗碱+cinnamtannin D1组(200 mg/kg+30 mg/kg),每组10只; 10只db/m小鼠作为正常组。灌胃给药5周后,进行口服葡萄糖耐量、胰岛素耐量试验,检测空腹血糖及甘油三酯(TG)、总胆固醇(TC)、游离脂肪酸(NEFA)、谷丙转氨酶(ALT)、天门冬氨酸转氨酶(AST)水平。结果与对照组比较,小檗碱组、小檗碱+cinnamtannin D1组口服葡萄糖耐量、胰岛素耐量有所改善,空腹血糖及血清TG、NEFA水平显著降低(P <0. 05,P <0. 01,P <0. 001),但仅后一组肝脏TG水平显著降低(P <0. 01);与小檗碱组比较,小檗碱+cinnamtannin D1组空腹血糖、胰岛素耐量AUC显著降低(P <0. 05)。结论交泰丸中小檗碱联合cinnamtannin D1可有效改善2型糖尿病小鼠症状,可能具有协同作用。
AIM To study the synergistic anti-glycemia effects of berberine and cinnamtannin D1 in Jiaotai Pills.METHODS Forty db/db mice were randomly divided into control group(0.5%CMC-Na),metformin group(150 mg/kg),berberine group(200 mg/kg)and berberine+cinnamtannin D1 group(200 mg/kg+30 mg/kg),ten mice in each group;and another ten db/m mice were recruited into the normal group.After 5-week corresponding intragastric administration,the mice had their oral glucose tolerance and insulin tolerance tested,as well as the levels of fasting blood glucose and triglyceride(TG),total cholesterol(TC),glutamic-pyruvic transaminase(ALT),and aspartate transaminase(AST).RESULTS Compared with the control group,both the berberine group and the berberine+cinnamtannin D1 group demonstrated improved oral glucose tolerance and insulin tolerance,in addition to the significantly decreased fasting blood glucose and serum TG,NEFA levels(P<0.05,P<0.01,P<0.001),markedly reduced liver TG level(P<0.01,only observable in the berberine+cinnamtannin D1 group).The berberine+cinnamtannin D1 group was superior to the berberine group in terms of significantly decreased fasting blood glucose and insulin tolerance AUC(P<0.05).CONCLUSION The effective alleviation of conditions of type 2 diabetic mice due to berberine and cinnamtannin D1 in Jiaotai Pills demonstrate their synergetic effects.
作者
王雪萍
张皓月
王婷
李医明
陈凯先
王贺瑶
贾琦
WANG Xue-ping;ZHANG Hao-yue;WANG Ting;LI Yi-ming;CHEN Kai-xian;WANG He-yao;JIA Qi(School of Pharmacy,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China)
出处
《中成药》
CAS
CSCD
北大核心
2018年第12期2613-2618,共6页
Chinese Traditional Patent Medicine
基金
国家自然科学基金(81773791)
上海市自然科学基金(15ZR1441200)
上海市优秀学术带头人基金(16XD1403500)
上海市中药药效物质E-研究院项目(E14017)
作者简介
王雪萍(1990—),女,硕士生,从事代谢性疾病研究。Tel:15000425698,E-mail:xueping723@163.com;通信作者:王贺瑶(1963-),女,研究员,从事代谢性疾病新药发现与药理学研究。Tel:(021)50805785,E-mail:hywang@simm;通信作者:贾琦(1963-),女,副教授,从事中药活性成分和结构修饰研究。Tel:(021)51322207,E-mail:q_jia@126.comac.cn.
